VEGFA and neoplasm: TACTICS trial provided a theoretical framework for the sequential therapy of Lenvatinib/Sorafenib and TACE, suggesting that the use of anti-VEGF agents prior to initial TACE treatment can correct tumour vasculature and improve drug delivery, thereby enhancing the anti-tumour efficacy of TACE, particularly in patients with tumour burdens exceeding the up-to-seven criteria, showing beneficial effects on PFS and OS (29–31).